

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Review Proposal Project

Review of Technology Appraisal No.100; Capecitabine and oxaliplatin in the adjuvant of stage III (Dukes' C) colon cancer

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Actavis UK (oxaliplatin) • Hospira UK Limited (oxaliplatin) • Medac UK (oxaliplatin) • Roche Products (capecitabine) • Sanofi-Synthelabo (oxaliplatin) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Beating Bowel Cancer • Black Health Agency • Bowel Cancer UK • CANCERactive • Cancer Black Care • Cancer Equality • Chinese National Healthy Living Centre • Colostomy Association • Confederation of Indian Organisations • CORE - The Digestive Disorders Foundation • Counsel and Care • Equalities National Council • Helen Rollason Heal Cancer Charity • Help the Aged and Age Concern • Ia: Ileostomy and Internal Pouch Support Group • Lynn's Bowel Cancer Campaign • Macmillan Cancer Support • Maggie's Centres 	<p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Cancer Care Cymru • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Public Health Service for Wales • NHS Alliance • NHS Confederation • NHS Purchasing and Supply Agency • NHS Quality Improvement Scotland • Scottish Medicines Consortium <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • Hospira UK (fluorouracil, levofolinic acid) • Mayne Pharma (fluorouracil) • Medac UK (fluorouracil) • Pfizer (irinotecan hydrochloride) • Wyeth Pharmaceuticals (calcium levofolinate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bowel & Cancer Research • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute

National Institute for Health and Clinical Excellence

Review of Technology Appraisal No.100; Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer

Issue date: August 2009

Appendix A

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Marie Curie Cancer Care • Muslim Council of Great Britain • Muslim Health Network • National Cancer Alliance • National Council for Palliative Care • Ostomy Lifestyle Centre • Pelican Cancer Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Sue Ryder Care • Teenage Cancer Trust • Tenovus Cancer Information Centre <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • Association of Coloproctologists of Great Britain • Association of Surgeons of Great Britain and Ireland • British Association for Services to the Elderly • British Association of Surgical Oncology • British Geriatrics Society • British Oncological Association • British Psychosocial Oncology Society • British Society of Gastroenterology • Cancer Network Pharmacists Forum • Cancer Research UK • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians, Medical Oncology Joint Special Committee • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine – 	<ul style="list-style-type: none"> • National Cancer Research Network • National Institute for Health Research • Policy Research Institute on Ageing and Ethnicity (PRIAE) • Research Institute for the Care of Older People (RICE) <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> • Assessment Group TBC • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Cancer <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • TBC

National Institute for Health and Clinical Excellence

Review of Technology Appraisal No.100; Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer

Issue date: August 2009

Consultees	Commentators (no right to submit or appeal)
<p>Intellectual Disabilities Forum</p> <ul style="list-style-type: none"> • United Kingdom Clinical Pharmacy Association • United Kingdom Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • Enfield PCT • Redcar and Cleveland PCT • Welsh Assembly Government 	

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).